Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLAMBA in Ragweed-Allergic Rhinitis (EEC Model)
NCT00537355Phase 2Completed
- Sponsor
- Dynavax Technologies
- Start
- Sep 2007
- Primary completion
- Mar 2008
- Modality
- Antisense DNA, Prophylactic Vaccines, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate in seasonal allergic rhinitis (SAR), sponsored by Dynavax Technologies. Started Sep 2007; status: completed.
02
Drugs
amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT00537355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00537355.